Description
Composition
active ingredient: oxolin;
1 g of the ointment contains 2.5 mg of oxolin;
excipients: polyethylene glycol 4000; stearyl alcohol; glycerin; citric acid, monohydrate; dimethicone; lavender essential oil; propylene glycol.
Dosage form
Ointment.
Main physical and chemical properties: the ointment is white or light yellow in color. A pinkish tint may appear during storage.
Pharmacotherapeutic group
Medications used for cough and cold diseases. Other cold remedies. ATC code: R05X.
Pharmacological properties
Pharmacodynamics.
Oxolin is an antiviral agent for external use, with virucidal activity, blocking the binding sites of the influenza virus (mainly type A2) on the cell membrane, protecting the cells from viral penetration. Oxolin is also effective against Herpes simplex, herpes zoster, adenoviruses, viruses causing infectious warts, and molluscum contagiosum.
Pharmacokinetics.
The medicinal product is non-toxic. When applied topically, it does not have systemic effects and does not accumulate in the body. When applied to mucous membranes, 20% is absorbed and is mostly excreted by the kidneys within 24 hours.
Indications
Prevention of influenza; treatment of viral rhinitis.
Contraindications
Individual hypersensitivity to the active ingredient or other components of the product.
Interactions with other medicinal products and other types of interactions
Simultaneous intranasal use with adrenergic agents may lead to drying of the nasal mucosa.
Special precautions for use
The ointment is not intended for application to the eye mucosa. The product should not be applied to damaged skin.
OXOLIN LAVENDER contains propylene glycol, which may cause skin irritation.
Stearyl alcohol may cause local skin reactions (e.g., contact dermatitis).
Use during pregnancy or breastfeeding
Safety data is unavailable, so the use of the product is not recommended during these periods.
Ability to influence the speed of reaction when driving vehicles or operating machinery
The product does not affect the ability to drive vehicles or operate other potentially dangerous machinery.
Method of use and dosage
For prevention of influenza: Apply 2–3 times a day to the nasal mucosa for 25 days or upon contact with infected individuals.
For treatment of viral rhinitis: Apply 2–3 times a day to the nasal mucosa for 3–4 days.
Children.
Safety and efficacy data for the use of the product in children is unavailable.
Overdose
Overdose cases are unknown. In case of overdose, possible symptoms include a burning sensation, skin and mucous membrane irritation at the application site, and rhinitis. Hypersensitivity reactions may occur.
Treatment: discontinue use of the product and wash any residual ointment with warm water.
Side effects
A burning sensation at the application site, which quickly subsides, rhinitis, and a blue discoloration of the mucosa may occur. Hypersensitivity reactions may also develop.
Reporting of suspected side effects.
Reporting suspected side effects after the registration of the medicinal product is important. It allows monitoring the benefit/risk ratio when using this product. Healthcare professionals, as well as patients or their legal representatives, should report any cases of suspected side effects or lack of efficacy through the Automated Information System for Pharmacovigilance at the following link: https://aisf.dec.gov.ua.
Expiration date
2 years. Do not use after the expiration date indicated on the packaging.
Storage conditions
Store at a temperature between 2 °C and 15 °C. After opening the tube, store at a temperature between 2 ºC and 8 ºC. Keep out of reach of children.
Packaging
3 g in a tube, 1 tube in a case, 1 case in a cardboard box or 10 g in a tube, 1 tube in a cardboard box.
Prescription category
Over-the-counter.
Manufacturer
Joint Ukrainian-Spanish Venture “Sperco Ukraine” LLC.
Manufacturer’s location and address of business.
21027, Ukraine, Vinnytsia, 600-richia str., 25.
Reviews
There are no reviews yet.